IRCT20080901001165N44招募中1 期
A Comparison Study on Safety & Efficacy of Repeated Intravenous Infusion of Allogeneic Mesenchymal Stem Cell from Different Sources in ARDS Patients: A Randomized, Double Blind, Clinical Trial Phase II
Bagheiat-allah University of Medical Sciences0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Signed informed consent voluntarily
- •Confirmed ARDS
- •SOFA score between 2-3 point
- •PaO2/FIO2 = 300 mmHg
- •Mild to Moderate pneumonia/ stay in the ICU <48 hours
- •Pulmonary imaging shows that the focus progress > 50% in 24-48 hours
排除标准
- •Co-Infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus
- •Liver or kidney SOFA score of more than 3 points; combined with other organ failure
- •Patients with malignant tumor
- •Pregnant or lactating women
- •Uncontrolled underling diseases
- •Pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia
- •In vitro life support (ECMO, ECCO2R, RRT)
研究者
相似试验
尚未招募
2 期
Effect of magnetic stimulation in the management of chronic migraineCTRI/2021/10/037215AIIMS Bhubaneswar
尚未招募
4 期
Options to Increase IVF SuccessCTRI/2024/03/063849A
尚未招募
1 期
Repetitive Transcranial Magnetic Stimulation with Virtual Reality Training to improve sensory-motor and cognitive deficits among stroke patientsCTRI/2023/07/055713I
进行中（未招募）
不适用
Comparison of safety and efficacy of the combination product QVA149A against the concurrent administration of the individual components, QAB149 and NVA237, in patients with chronic obstructive pulmonary disease (COPD)EUCTR2011-006050-91-SEovartis Pharma Service AG184
已完成
3 期
A study to compare the efficacy and safety of once daily QVA149 vs. the once daily concurrent administration of QAB149 plus NVA237 in patients with moderate to severe chronic obstructive pulmonary disease (CQVA149A2326)COPDchronic obstructive pulmonary disease10038716NL-OMON37459ovartis Pharma BV70